Myelodysplastic Syndrome
KER-050-D301:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
- Details
ClinicalTrials.gov ID:
NCT06499285
Diagnosis Type:
NA
USOR Number:
- Address
,
P: